Apr 24

Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

He answers the following questions:

  • Why do NK cell therapies hold promise in treating autoimmune disease?
  • What is the biggest technical/scientific challenge of developing NK-based therapies, and what has been Artiva’s experience addressing that challenge?
  • What are the best practices, or pitfalls to avoid, of cryopreservation?
  • How is Artiva approaching clinical trials of its NK cell-based candidate, since patients need multiple doses?
  • Can you tell us more about Artiva’s “manufacturing-first approach” and how it’s different from the traditional approach? How is Artiva approaching the closed process to minimize any variability?

Read the Q&A here.

Recent Posts

See All

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways....

Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK. He answers the following questions: Why do NK cell therapies hold promise in treating autoimmune disease? What is the biggest technical/scientific challenge of developing NK-based therapies, and what...

BiotechTV: Using NK Cell Therapies for Autoimmune Disease and Cancer with Artiva’s CEO

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the interview here.